China Pharmaceutical (600056.SH): Injection of Ganciclovir Passed Consistency Evaluation of Generic Drugs.

Zhijing Finance APP news, China Medicine (600056.SH) announced that recently, its wholly-owned subsidiary Hainan Tongyong Kangli Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangli Pharmaceutical") has received two Injection of Ganciclovir (hereinafter referred to as "the drug") "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The drug passed the consistency evaluation of generic drug quality and efficacy. Injection of Ganciclovir is mainly used for the treatment of cytomegalovirus infection in immunocompromised patients at risk of life or vision, as well as prevention of cytomegalovirus infection in organ transplant patients.